Takeda Pharmaceutical Company: Major launches and data readouts drive a pivotal strategic shift, with new leadership at the helm
Leadership transition is underway with a new CEO set to unveil strategy at December’s Capital Markets Day. Key launches include ORZEYFUL for narcolepsy and zasocitinib for immunology, both with competitive pricing and robust safety data. Multiple pipeline readouts are expected through 2027.Based on…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.